Dylan Daniel Email & Phone Number
@cytomx.com
LinkedIn matched
Who is Dylan Daniel? Overview
A concise factual answer block for searchers comparing this professional profile.
Dylan Daniel is listed as Vice President, Oncology & Immuno-Oncology Research and Translational Biology at CytomX Therapeutics at CytomX Therapeutics, based in San Francisco, California, United States. AeroLeads shows a work email signal at cytomx.com and a matched LinkedIn profile for Dylan Daniel.
Dylan Daniel previously worked as Vice President, Oncology & Immuno-Oncology Research and Translational Biology at Cytomx Therapeutics and Vice President, Oncology and Immuno-Oncology Research at Cytomx Therapeutics. Dylan Daniel holds Doctor Of Philosophy (Phd), Microbiology And Immunology from University Of Colorado Anschutz Medical Campus.
Email format at CytomX Therapeutics
This section adds company-level context without repeating Dylan Daniel's masked contact details.
AeroLeads found 1 current-domain work email signal for Dylan Daniel. Compare company email patterns before reaching out.
About Dylan Daniel
Dylan Daniel is a Vice President, Oncology & Immuno-Oncology Research and Translational Biology at CytomX Therapeutics at CytomX Therapeutics. He possess expertise in oncology, pharmacology, immunology, drug discovery, biotechnology and 16 more skills.
Listed skills include Oncology, Pharmacology, Immunology, Drug Discovery, and 17 others.
Dylan Daniel's current company
Company context helps verify the profile and gives searchers a useful next step.
Dylan Daniel work experience
A career timeline built from the work history available for this profile.
Vice President, Oncology And Immuno-Oncology Research
Senior Director, Oncology Research
Director, Immuno-Oncology Research
Director, Scientific Development
Chief Science Officer, Co-Founder
- Co-founded a biotechnology start-up based on technology from my former laboratory
- Developed pipeline strategy and clinical plans for novel oncology therapeutics including targeting CSF-1R in glioblastoma
- Devised approach to update and optimize an anti-mitotic agent for targeting various cancers alone and in combination with targeted therapies and immuno-oncology agents
- Led scientific assessment of novel candidate therapeutics for in-licensing
- Crafted successful venture capital pitches to obtain funding for asset development
Research Investigator Iii
- As project team leader, demonstrated proof-of-concept for a tumor macrophage targeting therapeutic program with a low molecular weight kinase inhibitor of CSF-1R
- Led immuno-oncology team of global GEM models allograft initiative to assess kinase inhibitors and immune checkpoint therapies in both autochthonous and allograft models
- Established in vivo strategy to enable lead selection and validate the specificity and efficacy of a proprietary linker-drug platform for global antibody-drug conjugate (ADC) team
- As project team leader, developed novel allosteric inhibitor for p21-activated kinase (PAK1/2) oncology project to treat KRAS mutant cancer indications
- Strategic leader for use of sophisticated mouse models to enable immuno-oncology therapeutic development
Scientist
- Led translational validation and in vivo assessment of TNF family death receptor oncology agents, Apo2L/TRAIL and DR5 monoclonal antibody, in non-Hodgkin’s lymphoma
- Elucidated the mechanism of action of agonistic DR5 monoclonal antibody
- Led validation of TNF-related weak inducer of apoptosis (TWEAK) target and tested pharmacologic activity of monoclonal antibodies as potential therapeutics
- Evaluated potential pipeline oncology targets for role in tumor growth and developed monoclonal antibody antagonists
Postdoctoral Researcher
- Immuno-Oncology of Genetically Engineered Mouse Models of CancerMentor: Douglas Hanahan
- Characterized the immune component of multiple GEM cancer models to enable assessment of immune surveillance hypothesis and novel immunotherapies
- Evaluated strategies to enhance efficacy of adoptive T cell immunotherapy in a transgenic mouse model of pancreatic beta-cell cancer
- Investigated immune editing/surveillance of cancer in a genetic model of human papillomavirus (HPV)-induced cervical cancer and evaluated a novel immunotherapy to enable human clinical trials
Dylan Daniel education
Doctor Of Philosophy (Phd), Microbiology And Immunology
Bachelor Of Science (Bs), Biochemistry, Biophysics And Molecular Biology
Frequently asked questions about Dylan Daniel
Quick answers generated from the profile data available on this page.
What company does Dylan Daniel work for?
Dylan Daniel works for CytomX Therapeutics.
What is Dylan Daniel's role at CytomX Therapeutics?
Dylan Daniel is listed as Vice President, Oncology & Immuno-Oncology Research and Translational Biology at CytomX Therapeutics at CytomX Therapeutics.
What is Dylan Daniel's email address?
AeroLeads has found 1 work email signal at @cytomx.com for Dylan Daniel at CytomX Therapeutics.
Where is Dylan Daniel based?
Dylan Daniel is based in San Francisco, California, United States while working with CytomX Therapeutics.
What companies has Dylan Daniel worked for?
Dylan Daniel has worked for Cytomx Therapeutics, Mi Bioresearch, Patronus Therapeutics Inc., Novartis Institutes For Biomedical Research, and Genentech.
How can I contact Dylan Daniel?
You can use AeroLeads to view verified contact signals for Dylan Daniel at CytomX Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Dylan Daniel attend?
Dylan Daniel holds Doctor Of Philosophy (Phd), Microbiology And Immunology from University Of Colorado Anschutz Medical Campus.
What skills is Dylan Daniel known for?
Dylan Daniel is listed with skills including Oncology, Pharmacology, Immunology, Drug Discovery, Biotechnology, Assay Development, Biology, and Cancer.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial